Prostate Cancer - Results from #240

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. June 22, 2022

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer. June 22, 2022

PROpel Phase III trial positive results of LYNPARZA® (olaparib) plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence June 21, 2022

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer June 21, 2022

Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer June 21, 2022

Blood-Based Liquid Biopsies for Prostate Cancer: Clinical Opportunities and Challenges June 21, 2022

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial June 21, 2022

Patient Decision-Making Factors in Aggressive Treatment of Low-Risk Prostate Cancer. June 21, 2022

From Therapy Resistance to Targeted Therapies in Prostate Cancer. June 21, 2022

Fibromodulin Gene Variants (FMOD) as Potential Biomarkers for Prostate Cancer and Benign Prostatic Hyperplasia. June 21, 2022

Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence. June 21, 2022

Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer. June 21, 2022

Navigation programs relevant for African American men with prostate cancer: a scoping review protocol. June 20, 2022

Pilot Study: PARP1 Imaging in Advanced Prostate Cancer. June 20, 2022

Prostate Cancer Eligible for Radical Prostatectomy: Self-Esteem of Patients and Forms of Coping with Stress. June 20, 2022

Cellular Damage in the Target and Out-Of-Field Peripheral Organs during VMAT SBRT Prostate Radiotherapy: An In Vitro Phantom-Based Study. June 20, 2022

Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer. June 20, 2022

Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases. June 17, 2022

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. June 17, 2022

Evolving Trends in the Management of Low-Risk Prostate Cancer. June 17, 2022

Page 13 of 1242

email news signup